Citations (25)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (6)
Wolfgang H Jost. (2013) Rasagiline in Parkinson's disease: the show must go on. Expert Opinion on Drug Safety 12:6, pages 797-800.
Read now
Read now
Julián Solís-García del Pozo, Sara Mínguez-Mínguez, Piet WJ de Groot & Joaquín Jordán. (2013) Rasagiline meta-analysis: a spotlight on clinical safety and adverse events when treating Parkinson's disease. Expert Opinion on Drug Safety 12:4, pages 479-486.
Read now
Read now
Thomas Müller. (2013) Detoxification and antioxidative therapy for levodopa-induced neurodegeneration in Parkinson’s disease. Expert Review of Neurotherapeutics 13:6, pages 707-718.
Read now
Read now
François Viallet, Séverine Pitel, Sylvie Lancrenon & Olivier Blin. (2013) Evaluation of the safety and tolerability of rasagiline in the treatment of the early stages of Parkinson’s disease. Current Medical Research and Opinion 29:1, pages 23-31.
Read now
Read now
Susan R. Meier-Davis, Kevin Dines, Fatima M. Arjmand, Richard Hamlin, Betsy Huang, Jainye Wen, Chad Christianson, Jutaro Shudo & Tetsuto Nagata. (2012) Comparison of oral and transdermal administration of rasagiline mesylate on human melanoma tumor growth in vivo. Cutaneous and Ocular Toxicology 31:4, pages 312-317.
Read now
Read now
Santiago Perez-Lloret & Olivier Rascol. (2011) Safety of rasagiline for the treatment of Parkinson's disease. Expert Opinion on Drug Safety 10:4, pages 633-643.
Read now
Read now
Articles from other publishers (19)
Zhi Xin Chew, Chooi Ling Lim, Khuen Yen Ng, Soi Moi Chye, Anna Pick Kiong Ling & Rhun Yian Koh. (2023) The Role of Monoamine Oxidase B Inhibitors in the Treatment of Parkinson’s
Disease - An Update. CNS & Neurological Disorders - Drug Targets 22:3, pages 329-352.
Crossref
Crossref
Wolfgang H. Jost. (2022) A critical appraisal of MAO-B inhibitors in the treatment of Parkinson’s disease. Journal of Neural Transmission 129:5-6, pages 723-736.
Crossref
Crossref
Robert A. Hauser, Nir Giladi, Werner Poewe, Jonathan Brotchie, Hadas Friedman, Sheila Oren & Pninit Litman. (2022) P2B001 (Extended Release Pramipexole and Rasagiline): A New Treatment Option in Development for Parkinson’s Disease. Advances in Therapy 39:5, pages 1881-1894.
Crossref
Crossref
Yu-Yan Tan, Peter Jenner & Sheng-Di Chen. (2022) Monoamine Oxidase-B Inhibitors for the Treatment of Parkinson’s Disease: Past, Present, and Future. Journal of Parkinson's Disease 12:2, pages 477-493.
Crossref
Crossref
Paolo Solla, Tommaso Ercoli, Carla Masala, Gianni Orofino, Laura Fadda, Davide Giacomo Corda, Ignazio Roberto Zarbo, Mario Meloni, Elia Sechi, Caterina Francesca Bagella & Giovanni Defazio. (2022) Rasagiline Withdrawal Syndrome in Parkinson’s Disease. Brain Sciences 12:2, pages 219.
Crossref
Crossref
Wolfgang H. Jost. 2022. NeuroPsychopharmacotherapy. NeuroPsychopharmacotherapy
2871
2889
.
Wolfgang H. Jost. 2020. NeuroPsychopharmacotherapy. NeuroPsychopharmacotherapy
1
19
.
Nobutaka Hattori, Atsushi Takeda, Shinichi Takeda, Akira Nishimura, Tadayuki Kitagawa, Hideki Mochizuki, Masahiro Nagai & Ryosuke Takahashi. (2019) Long-term, open-label, phase 3 study of rasagiline in Japanese patients with early Parkinson’s disease. Journal of Neural Transmission 126:3, pages 299-308.
Crossref
Crossref
Zhenxin Zhang, Jian Wang, Shengdi Chen, Chunfeng Liu, Baorong Zhang, Rong Peng, Shenggang Sun, Xiangru Sun, Gang Zhao, Qiumin Qu, Yansheng Li, Suiqiang Zhu, Xiaoping Pan, Ming Shao & Yanping Wang. (2018) Efficacy and safety of rasagiline in Chinese patients with early Parkinson’s disease: a randomized, double-blind, parallel, placebo-controlled, fixed-dose study. Translational Neurodegeneration 7:1.
Crossref
Crossref
Giuseppe Frazzitta, Roberto Maestri, Gabriella Bertotti, Giulio Riboldazzi, Natalia Boveri, Michele Perini, Davide Uccellini, Marinella Turla, Cristoforo Comi, Gianni Pezzoli & M. Felice Ghilardi. (2014) Intensive Rehabilitation Treatment in Early Parkinson’s Disease. Neurorehabilitation and Neural Repair 29:2, pages 123-131.
Crossref
Crossref
Joseph Jankovic, Elijahu Berkovich, Eli Eyal & Eduardo Tolosa. (2014) Symptomatic efficacy of rasagiline monotherapy in early Parkinson's disease: Post-hoc analyses from the ADAGIO trial. Parkinsonism & Related Disorders 20:6, pages 640-643.
Crossref
Crossref
Michele Pistacchi, Francesco Martinello, Manuela Gioulis & Sandro Zambito Marsala. (2013) Rasagiline and Rapid Symptomatic Motor Effect in Parkinson’s Disease: Review of Literature. Neurology and Therapy 3:1, pages 41-66.
Crossref
Crossref
Joseph JankovicLawrence W Elmer & Robert A Hauser. 2013. Parkinson’s Disease: Medical and Surgical Treatment. Parkinson’s Disease: Medical and Surgical Treatment
23
41
.
Sara Mínguez-Mínguez, Julián Solís-García del Pozo & Joaquín Jordán. (2013) Rasagiline in Parkinson's disease: A review based on meta-analysis of clinical data. Pharmacological Research 74, pages 78-86.
Crossref
Crossref
Ravi Kumar Konda, Babu Rao Chandu, B.R. Challa & Chandrasekhar B. Kothapalli. (2012) Bio-analytical method development and validation of Rasagiline by high performance liquid chromatography tandem mass spectrometry detection and its application to pharmacokinetic study. Journal of Pharmaceutical Analysis 2:5, pages 342-349.
Crossref
Crossref
Sheridan M. Hoy & Gillian M. Keating. (2012) Rasagiline. Drugs 72:5, pages 643-669.
Crossref
Crossref
Lawrence ElmerRobert A Hauser. (2011) Strategies for Parkinson’s disease care: prevention and management of motor fluctuations. Neurodegenerative Disease Management 1:5, pages 415-430.
Crossref
Crossref
Elizabeth A. Mazzio, Fran Close & Karam F.A. Soliman. (2011) The Biochemical and Cellular Basis for Nutraceutical Strategies to Attenuate Neurodegeneration in Parkinson’s Disease. International Journal of Molecular Sciences 12:1, pages 506-569.
Crossref
Crossref
L.M. Chahine & M.B. Stern. 2011. Monoamine Oxidase and their Inhibitors. Monoamine Oxidase and their Inhibitors
151
168
.